Biogen Diranersen - Questions Continue
July 15, 2026
Welcome to the new format of Greg’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.
Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.
This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
SUMMARY:
Biogen diranersen (formerly known as BIIB080) is an investigational drug designed to reduce the production of tau protein. There are concerns about diranersen because the Phase 2 CELIA trial showed the strongest evidence of slowed cognitive decline was seen at the lowest dose tested (60 mg every 24 weeks). Patients who got the highest and most frequent dose benefited the least. Yet, Biogen is moving forward with a Phase 3 trial.
My report includes:
the statement issued by Biogen at the Alzheimer’s Association International Conference in London yesterday
possible reasons why the Phase 2 CELIA trail may have missed its primary end point
a link to a new e-learning module on Tau